MedTrace Logo

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East

NCT02015286 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a Middle East, Multicenter, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in pediatric subjects using easypod™ electromechanical device for growth hormone treatment and to assess the level of adherence of subject receiving SAIZEN® via easypod™.

Conditions

  • Growth Disorders

Interventions

DEVICE

easypod™

Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™

Sponsors & Collaborators

  • Merck Serono Middle East FZ LLC

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck Serono Middle East FZ LLC

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02015286 on ClinicalTrials.gov